United Therapeutics Corporation annual operating income for fiscal 2025 was $1.5 billion, an increase of 4.8% from $1.4 billion in fiscal 2024. All figures are reported results from public filings — no estimates or projections.
| Operating Income (annual) | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Operating Income (EBIT) | $1.5B | $1.4B | $1.2B | $980M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Operating Income (quarterly) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Operating Income (EBIT) | $326M | $358M | $389M | $386M | $383M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More UTHR metrics: Revenue · Gross Profit · Net Income · EPS · Free Cash Flow
All UTHR financial statements → Interactive UTHR charts →
About TickerBase · Data methodology & sources